Sandoz Group AG (SDZNY)
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
Sector: Drug Manufacturers - Specialty & Generic
Industry: Drug Manufacturers - Specialty & Generic
Sandoz Group AG
OTC:SDZNYHealthcare · Drug Manufacturers - Specialty & Generic
-0.71%$100.97
CLOSED · Nov 6Prev close$101.69-0.71%Close$100.97
Mkt Cap$43.7B
Float416.44M
O/S432.76M
VOL19K sh
$ Vol$1.93M
RVOL0.70×
Inst Own-
SI<0.1%
Div Yield1.01%
Dilution
Financials Summary
Revenue$11.15B
Net Income$919.12M
Total Assets$22.03B
Free Cash Flow$810M
Debt & Equity
Debt 38%
Equity 62%
Total Debt$5.68B
Total Equity$9.38B
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in SDZNY's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$22.03B
Liabilities$12.65B
Accounts Receivable$2.77B
Accounts Payable$1.85B
Inventory$2.85B
PP&E (Net)$2.78B
Goodwill$8.01B
Intangible Assets$1.87B
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Revenue | $11.15B | $10.38B | $11.66B | $9.3B | $9.62B | $9.67B |
| YoY Growth | 7.4% | -11.0% | 25.4% | -3.3% | -0.6% | - |
| Cost of Revenue | $5.91B | $5.46B | $6.33B | $4.93B | $5.08B | $5.52B |
| Gross Profit | $5.24B | $4.93B | $5.33B | $4.38B | $4.54B | $4.7B |
| Gross Margin | 47.0% | 47.4% | 45.7% | 47.0% | 47.2% | 48.6% |
| Research and Development | $1.06B | $932M | $1.08B | $860.2M | $910.82M | $926.77M |
| Selling, General, and Administrative | $2.54B | $2.43B | $2.79B | $24K | $2.13B | $2.26B |
| Other | -$71.4M | $1.25B | $1.02B | $2.28B | -$7M | -$6.37M |
| Total Operating Expenses | $3.53B | $4.62B | $4.9B | $3.14B | $3.03B | $3.18B |
| Operating Income (EBIT) | $1.71B | $307M | $438.26M | $1.24B | $1.51B | $1.52B |
| Operating Margin | 15.4% | 3.0% | 3.8% | 13.3% | 15.7% | 15.7% |
| Interest Expense | $221.23M | $251M | $202M | $90.87M | $66.99M | $79.62M |
| Interest Income | $0 | $43M | $31M | $8.26M | $5M | $3.18M |
| Other Income (Expense) | -$500.79M | -$318M | -$286.33M | -$136.96M | -$195.96M | $0 |
| Income Before Tax (EBT) | $1.21B | -$11M | $151.93M | $1.1B | $1.31B | $706.92M |
| Income Tax Expense | $294.64M | -$12M | $58.43M | $251.92M | $402.92M | $242.32M |
| Net Income | $919.12M | $1M | $89.99M | $847.75M | $907.82M | $490.46M |
| Net Income Margin | 8.2% | 0.0% | 0.8% | 9.1% | 9.4% | 5.1% |
| Supplementary Data | ||||||
| EPS | 2.13 | 0.00 | 0.21 | 1.97 | 2.11 | 1.14 |
| Diluted EPS | 2.11 | 0.00 | 0.21 | 1.97 | 2.11 | 1.14 |
| Weighted Average OS | 431.12M | 429.90M | 429.90M | 431.00M | 431.00M | 431.00M |
| EBITDA | $2.26B | $742M | $1B | $1.73B | $1.87B | $1.53B |
| EBITDA Margin | 20.3% | 7.1% | 8.6% | 18.6% | 19.4% | 15.8% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Assets | ||||||
| Current Assets | ||||||
| Cash and Cash Equivalents | $1.74B | $1.19B | $1.3B | $80.01M | $39.86M | $38.99M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $1.74B | $1.19B | $1.3B | $80.01M | $39.86M | $38.99M |
| Accounts Receivable | $2.77B | $3.15B | $3.54B | $2.3B | $3.27B | $2.98B |
| Inventory | $2.85B | $2.8B | $3.16B | $2.12B | $2B | $2.35B |
| Other Current Assets | $507M | $443M | $696.53M | $1.34B | $240.13M | $274.94M |
| Total Current Assets | $8.16B | $7.8B | $8.85B | $5.98B | $5.54B | $5.64B |
| Long-Term Assets | ||||||
| Property, Plant & Equipment Net | $2.78B | $1.99B | $2.16B | $1.9B | $1.93B | $2.07B |
| Goodwill | $8.01B | $7.47B | $8.87B | $7.44B | $7.66B | $7.92B |
| Intangible Assets | $1.87B | $1.48B | $1.83B | $1.45B | $1.58B | $1.54B |
| Long-Term Investments | $31.73M | $21.78M | $26.56M | $22.01M | $22.92M | $21.99M |
| Deferred Tax Assets | $924M | $954M | $836.78M | $713.26M | $714.42M | $707.84M |
| Other Long-Term Assets | $250.27M | $198.22M | $138.23M | $1.51B | $1.62B | $1.57B |
| Total Long-Term Assets | $13.87B | $12.11B | $13.86B | $11.59B | $11.93B | $12.3B |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $22.03B | $19.91B | $22.71B | $17.55B | $17.48B | $17.94B |
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payable | $1.85B | $1.52B | $1.86B | $1.19B | $1.11B | $1.07B |
| Short-Term Debt | $603M | $129M | $314.38M | $4.03B | $4.78B | $5.13B |
| Current Income Tax Payable | $800M | $644M | $562.63M | $231.08M | $199.28M | $451.9M |
| Current Unearned Revenue | $0 | $0 | $0 | $3M | $3.99M | $4M |
| Other Current Liabilities | $3.29B | $3.79B | $3.44B | $1.74B | $1.56B | $1.71B |
| Total Current Liabilities | $6.89B | $6.31B | $6.66B | $7.91B | $8.33B | $9.15B |
| Long-Term Liabilities | ||||||
| Long-Term Debt | $4.7B | $4.39B | $4.65B | $30.01M | $16.94M | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $207M | $259M | $294.51M | $286.1M | $292.94M | $327.92M |
| Other Long-Term Liabilities | $535M | $511M | $696.53M | $479.17M | $597.84M | $611M |
| Total Long-Term Liabilities | $5.75B | $5.44B | $5.93B | $883.32M | $1.01B | $1.07B |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $12.65B | $11.74B | $12.59B | $8.8B | $9.35B | $10.22B |
| Stockholders' Equity | ||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $25M | $25M | $28.05M | $108K | $0 | $0 |
| Retained Earnings | $0 | $0 | $7.93B | -$25K | $8.23B | $7.55B |
| Comprehensive Income & Other | $0 | $0 | $553.78M | -$172.06M | -$103.63M | $159.96M |
| Other Stockholders' Equity | $9.36B | $8.14B | $2.15B | $0 | -$103.63M | $159.96M |
| Total Equity | $9.38B | $8.16B | $10.1B | $83K | $8.12B | $7.71B |
| Minority Interest | $1M | $1M | $8.85M | $12M | $9.96M | $8M |
| Total Liabilities and Equity | $22.03B | $19.91B | $22.7B | $8.8B | $17.47B | $17.93B |
| Supplementary Data | ||||||
| Total Debt | $5.68B | $4.85B | $5.32B | $4.18B | $4.93B | $5.3B |
| Net Debt | $3.94B | $3.66B | $4.02B | $4.1B | $4.89B | $5.26B |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Operating Activities | ||||||
| Net Income | $914M | $1M | $93.49M | $919.05M | $907.82M | $462.6M |
| Depreciation & Amortization | $545M | $502M | $613.56M | $492M | $488.84M | $697.14M |
| Deferred Income Tax | $0 | $0 | $0 | -$30.98M | $0 | $0 |
| Stock-Based Compensation | $102M | $88M | $29.22M | $61.02M | $62.95M | $68.09M |
| Changes in Working Capital: | ||||||
| Accounts Receivable | -$103M | $256M | -$317.17M | -$178.35M | -$73.99M | $210.25M |
| Inventory | $227M | -$277M | -$607.04M | -$272.53M | $176.97M | -$106.63M |
| Accounts Payable | $0 | $0 | $533.52M | $131.26M | $92.98M | -$156.93M |
| Other Working Capital | $739M | -$344M | -$384.15M | $118.23M | -$258.95M | -$675.01M |
| Total Working Capital Change | $863M | -$365M | -$774.84M | -$201.39M | -$62.99M | -$728.32M |
| Other Non-Cash Items | -$830M | $430M | $461.63M | -$16.7M | -$42.88M | $599.93M |
| Net Cash from Operating | $1.59B | $656M | $423.06M | $1.22B | $1.35B | $1.1B |
| Investing Activities | ||||||
| Capital Expenditures | -$493M | -$404M | -$663.75M | -$440.94M | -$417.92M | -$350.33M |
| Acquisitions | -$260M | -$182M | -$21.04M | -$30.98M | -$333.94M | -$273.89M |
| Purchases of Investments | -$4M | -$4M | -$5.84M | -$6.2M | -$3M | -$2.12M |
| Sales of Investments | $2M | $1M | $2.1M | $1.03M | $2M | $1.06M |
| Other Investing Activities | -$225M | -$151M | -$29.04M | $12.15M | $61.99M | $76.56M |
| Net Cash from Investing | -$980M | -$740M | -$717.57M | -$464.93M | -$690.87M | -$548.72M |
| Financing Activities | ||||||
| Debt Repaid | -$232M | -$670M | -$4.47B | -$17.3M | $26.94M | $43.06M |
| Common Stock Issuance | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock Repurchases | $0 | -$12M | $0 | $0 | $0 | $0 |
| Dividends Paid | -$315M | -$215M | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$76M | -$91M | -$3.16B | -$895.26M | -$629.94M | -$504.66M |
| Net Cash from Financing | -$197M | $242M | $1.45B | -$831.47M | -$656.87M | -$547.72M |
| Forex Effect | $131M | -$76M | $52.59M | $10.81M | -$3.84M | $35.98M |
| Net Change in Cash | $548M | $82M | $1.21B | $34M | $2.16M | $39.05M |
| Supplementary Data | ||||||
| Operating Cash Flow | $1.59B | $656M | $423.06M | $1.22B | $1.35B | $1.1B |
| Capital Expenditure | -$784M | -$596M | -$730.43M | -$440.94M | -$417.92M | -$350.33M |
| Free Cash Flow | $810M | $60M | -$307.36M | $821.99M | $935.82M | $815.31M |
| Cash at Beginning | $1.19B | $1.11B | $86.48M | $40M | $37.7M | $35.81M |
| Cash at End | $1.74B | $1.19B | $1.3B | $74.03M | $39.86M | $38.99M |